Biosimilars

Global healthcare costs and demands are changing, and it’s time to look beyond mammalian cell lines.

After many years of clinical trial failures in Alzheimer’s disease, pharma sees some positive results – although caution is recommended.

A new not-for-profit company will manufacture important generics in the US

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.

Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.

WHO is investigating the potential of certain biosimilars in a prequalification pilot program.

Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Why does the full potential of biosimilars remain untapped? Four experts weigh in.